GlaxoSmithKline plc (LON:GSK) received a GBX 1,600 ($21.04) target price from equities research analysts at Morgan Stanley in a research report issued to clients and investors on Wednesday, October 18th. The brokerage currently has a “sell” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 17.60% from the stock’s previous close.
Several other analysts have also recently commented on the company. Deutsche Bank AG reissued a “hold” rating and issued a GBX 1,720 ($22.62) price target on shares of GlaxoSmithKline plc in a report on Friday, June 30th. UBS AG set a GBX 1,600 ($21.04) price objective on GlaxoSmithKline plc and gave the stock a “neutral” rating in a report on Wednesday, July 26th. Bryan, Garnier & Co reissued a “neutral” rating and set a GBX 1,710 ($22.49) price target on shares of GlaxoSmithKline plc in a research report on Tuesday, September 19th. Credit Suisse Group reissued a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 21st. Finally, Citigroup Inc. downgraded GlaxoSmithKline plc from a “buy” rating to a “neutral” rating and set a GBX 1,700 ($22.36) price objective for the company. in a research report on Wednesday, July 5th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,591.75 ($20.94).
GlaxoSmithKline plc (LON:GSK) traded down GBX 0.50 ($0.01) on Wednesday, reaching GBX 1,360.50 ($17.89). The company had a trading volume of 6,536,227 shares.
GlaxoSmithKline plc (LON:GSK) last released its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, beating analysts’ consensus estimates of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%.
TRADEMARK VIOLATION NOTICE: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/glaxosmithkline-plc-gsk-given-a-gbx-1600-price-target-at-morgan-stanley/1724086.html.
In other GlaxoSmithKline plc news, insider Urs Rohner purchased 473 shares of the business’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Also, insider Simon Dingemans purchased 1,076 shares of the business’s stock in a transaction on Thursday, October 12th. The shares were acquired at an average price of GBX 1,527 ($20.08) per share, with a total value of £16,430.52 ($21,610.57). In the last quarter, insiders purchased 1,574 shares of company stock valued at $2,398,888.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with our FREE daily email newsletter.